miR‑142‑5p promotes renal cell tumorigenesis by targeting TFAP2B

Zhu,Maoshu; Zou,Liangneng; Lu,Fuhua; Ye,Ling; Su,Bin; Yang,Kaichun; Lin,Minghua; Fu,Jianqian; Li,Yongwu

doi:10.3892/ol.2020.12187

miR‑142‑5p promotes renal cell tumorigenesis by targeting TFAP2B

Authors:
- Maoshu Zhu
- Liangneng Zou
- Fuhua Lu
- Ling Ye
- Bin Su
- Kaichun Yang
- Minghua Lin
- Jianqian Fu
- Yongwu Li
View Affiliations

Affiliations: The Central Laboratory, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Geriatrics, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Nephrology, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Respiratory Medicine, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Pharmacy Education, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Emergency, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Pathology, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Medical Oncology, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China
Published online on: October 5, 2020 https://doi.org/10.3892/ol.2020.12187
Article Number: 324
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transcription factor AP‑2 β (TFAP2B) serves an important role in kidney development. MicroRNAs (miRNAs) regulate carcinogenic pathways and have gained increasing attention owing to their association with human clear cell renal cell carcinoma (ccRCC) tumorigenesis. However, whether miRNAs could affect renal cell tumorigenesis by regulating TFAP2B expression has not been identified. The aim of this study was to investigate the effects of miRNA on TFAP2B and its potential role in cell growth, invasion and migration. PCR, western blot and dual luciferase reporter assays were performed to analyze the effects of miR‑142‑5p on TFAP2B. Furthermore, MTT, flow cytometry, wound healing and Transwell migration assays were used to analyze the effect of miR‑142‑5p on cell proliferation and migration. The results demonstrated that miR‑142‑5p targeted TFAP2B and downregulated the expression of TFAP2B at the mRNA and protein levels, promoting cell proliferation and migration in two ccRCC cell lines, 786‑O and A‑498. This phenomenon supported the theory that miR‑142‑5p may function as an oncogene in ccRCC. The potential clinical significance of miR‑142‑5p as a biomarker and a therapeutic target provides rationale for further investigation into miR‑142‑5p‑mediated molecular pathways and how these may be associated with ccRCC development.

View Figures

View References

1	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Disease Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
3	Cho E, Adami HO and Lindblad P: Epidemiology of renal cell cancer. Hematol Oncol Clin North Am. 25:651–665. 2011. View Article : Google Scholar : PubMed/NCBI
4	Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG and Kolenko VM: Resistance to systemic therapies in clear cell renal cell carcinoma: Mechanisms and management strategies. Mol Cancer Ther. 17:1355–1364. 2018. View Article : Google Scholar : PubMed/NCBI
5	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
6	Tippu Z, Au L and Turajlic S: Evolution of renal cell carcinoma. Eur Urol Focus S2405-S4569. 30383–30389. 2020.
7	Mennitto A, Verzoni E, Grassi P, Ratta R, Fucà G and Procopio G: Multimodal treatment of advanced renal cancer in 2017. Expert Rev Clin Pharmacol. 10:1395–1402. 2017. View Article : Google Scholar : PubMed/NCBI
8	Eckert D, Buhl S, Weber S, Jäger R and Schorle H: The AP-2 family of transcription factors. Genome Biol. 6:2462005. View Article : Google Scholar : PubMed/NCBI
9	Lüscher B, Mitchell PJ, Williams T and Tjian R: Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev. 3:1507–1517. 1989. View Article : Google Scholar : PubMed/NCBI
10	Zeng YX, Somasundaram K and el-Deiry WS: AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet. 15:78–82. 1997. View Article : Google Scholar : PubMed/NCBI
11	Auman HJ, Nottoli T, Lakiza O, Winger Q, Donaldson S and Williams T: Transcription factor AP-2gamma is essential in the extra-embryonic lineages for early postimplantation development. Development. 129:2733–2747. 2002.PubMed/NCBI
12	Moser M, Pscherer A, Roth C, Becker J, Mücher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R and Fässler R: Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev. 11:1938–1948. 1997. View Article : Google Scholar : PubMed/NCBI
13	Fu L, Shi K, Wang J, Chen W, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, et al: TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Mol Cancer. 13:892014. View Article : Google Scholar : PubMed/NCBI
14	Konta T, Ichikawa K, Suzuki K, Kudo K, Satoh H, Kamei K, Nishidate E and Kubota I: A microarray analysis of urinary microRNAs in renal diseases. Clin Exp Nephrol. 18:711–717. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wong NW, Chen Y, Chen S and Wang X: OncomiR: An online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics. 34:713–715. 2018. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K, Ren W, Zhang X, Shu P and Zhang D: miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis. Biomed Pharmacother. 92:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Liu Z, Fang X and Yang H: MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515. 2017. View Article : Google Scholar : PubMed/NCBI
19	Cheng D, Li J, Zhang L and Hu L: miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway. Oncol Lett. 17:1363–1371. 2019.PubMed/NCBI
20	Liu L, Liu S, Duan Q, Chen L, Wu T, Qian H, Yang S, Xin D, He Z and Guo Y: MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3. Am J Transl Res. 9:2394–2402. 2017.PubMed/NCBI
21	Oya M, Mikami S, Mizuno R, Miyajima A, Horiguchi Y, Nakashima J, Marumo K, Mukai M and Murai M: Differential expression of activator protein-2 isoforms in renal cell carcinoma. Urology. 64:162–167. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and Copland JA: Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. 5:e106962010. View Article : Google Scholar : PubMed/NCBI